Evidence map›Paper›PMID 34033165›Full record

ArticleCytopathology : official journal of the British Society for Clinical Cytology2021

SARS-CoV-2 RNA may rarely be present in a uterine cervix LBC sample at the asymptomatic early stage of COVID 19 disease.

Ondrej Ondič, Kateřina Černá, Iva Kinkorová-Luňáčková, Jana Němcová, Bořivoj Mejchar, Jan Chytra, Jiří Bouda

Open access · bronzeAbstract read
In one paragraph

Article in Cytopathology : official journal of the British Society for Clinical Cytology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The Mechanisms of Ferroptosis Under Hypoxia.Cellular and molecular neurobiology · 2023
    Review
  4. Article
  5. Article
  6. SARS-CoV-2 RNA may rarely be present in a uterine cervix LBC sample at the asymptomatic early stage of COVID 19 disease.Cytopathology : official journal of the British Society for Clinical Cytology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ondrej OndičDepartment of Pathology, Medical Faculty, Charles University and Charles University Hospital Pilsen, Pilsen, Czech Republic.ORCID 0000-0002-4038-5641
Kateřina ČernáDepartment of Pathology, Medical Faculty, Charles University and Charles University Hospital Pilsen, Pilsen, Czech Republic.
Iva Kinkorová-LuňáčkováBioptická Laboratoř, s.r.o., Pilsen, Czech Republic.
Jana NěmcováDepartment of Pathology, Medical Faculty, Charles University and Charles University Hospital Pilsen, Pilsen, Czech Republic.
Bořivoj MejcharPrivate Gynaecologist Office, Pilsen, Czech Republic.
Jan ChytraDepartment of Gynecology and Obstetrics, Medical Faculty, Charles University and Charles University Hospital Pilsen, Pilsen, Czech Republic.
Jiří BoudaDepartment of Gynecology and Obstetrics, Medical Faculty, Charles University and Charles University Hospital Pilsen, Pilsen, Czech Republic.
Charles University · CZBiopticka Laborator (Czechia) · CZ

Funding

Ministry of Health of the Czech Republic FNPl 00669806
6 · The paper itself

Abstract

objectiveCurrently, it is thought that uterine cervix mucosal samples present a low risk of SARS-CoV-2 exposure. So far, there is no evidence of SARS-CoV-2 detection in Papanicolaou (Pap) smears. Nevertheless, clinicians could be exposed unaware to the coronavirus while performing and handling a Pap smear. We aimed to retrospectively evaluate the presence of SARS-CoV-2 RNA in cervical liquid-based cytology (LBC) samples in women who tested positive for a nasopharyngeal COVID-19 PCR test.

methodsFrom our laboratory database, we identified patients with data on a cervical cancer screening LBC sample paired with a positive nasopharyngeal COVID-19 PCR test. Relevant LBC samples taken within an incubation period of 14 days and post-onset RNA shedding interval of 25 days were subsequently tested for SARS-CoV-2 RNA using RT-PCR tests.

resultsThe study group consisted of 102 women. Of those, 23 LBC samples were tested. SARS-CoV-2 RNA was detected in one LBC sample from a 26-year-old asymptomatic woman taken six days before reporting headaches and knee arthralgia with a positive nasopharyngeal SARS-CoV-2 RT-PCR test.

conclusionsIt is possible to detect SARS-CoV-2 RNA in cervical LBC samples at an early asymptomatic stage of COVID-19. In general, this finding is infrequent in asymptomatic women who tested SARS-CoV-2 positive within an incubation of 14 days and a post-onset RNA shedding period of 25 days. We fully support the current thinking that cervical LBC samples from asymptomatic women pose a low risk of SARS-CoV-2 exposure and can be handled in the frame of good microbiological practice and procedures.

Indexed as

COVID-19COVID-19 Nucleic Acid TestingPapanicolaou TestSARS-CoV-2Vaginal SmearsAdultFemaleHumansMiddle AgedRetrospective StudiesUterine Cervical NeoplasmscoronavirusCOVID-19LBCPAP smearPCRSARS-CoV-2

Identifiers

PMID34033165
PMCPMC8237001
OpenAlexW3164007777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.